PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?

Alexander R. Haug

Abstract

Great efforts have been made in dosimetry for individualizing PRRT. However, many centers do not use dosimetry and its results hardly influence treatment. A reason for that is that reliable thresholds for organs-at-risk, kidneys and bone marrow, and treatment response are lacking. The nuclear medicine community must provide solid data from large trials delivering reliable thresholds, which then help to tailor PRRT according to organ doses (in order to reduce toxicity or increase treatment activity) or tumor doses (in order to increase activity to meet the response-threshold). Otherwise, development of radionuclide therapies will be done like big pharmaceutical companies do it currently: classical dose escalation studies and agreement on acceptable toxicity probabilities. Therapeutic radiopharmaceuticals will then be handled like other drugs, which on the other hand will increase availability of radionuclide therapies.

Keywords: Neuroendocrine tumor, Dosimetry, 177Lu, DOTATATE, PRRT

Background

In treatment of oncologic diseases, different treatment strategies have been implemented. Most therapies follow a fixed dose concept, administering a pre-defined fixed dose to a given patient. Typical examples for the fixed dose concept are not only targeted therapies such as sunitinib, everolimus, and erlotinib, but also radionuclide therapies such as most radiiodine therapies in thyroid cancer or PRRT with [177Lu]DOTATATE and [177Lu]PSMA. More patient-adapted treatments follow a body-weight- or body-surface-based concept, which calculates the dose to the patients’ weight or body-surface. Typical examples are some chemotherapeutics such as 5-FU and treatments with antibodies. A third concept modulates the treatment according to given clinical factors such as tumor stage and proven risk factors. Radiation therapy is partly an example, where the dose to a given tumor is intensified in case of risk factors such as high-risk prostate cancer or locally advanced head-and-neck cancer. Radioiodine therapy of thyroid cancer serves as another example, in which the administered activity is based on patient age, histological subtype, or T-, and N-stage. Nuclear Medicine has made great efforts in the recent past, particularly in order to further improve PRRT using dosimetry for a tailored treatment to an individual patient. These efforts have been translated into clinical routine, subsequently with the need for frequent costly scintigraphic measurements for measuring absorbed doses to critical organs. In order to justify these efforts, the impact of dosimetry on radionuclide therapy has to be evaluated carefully. Consequently, an increasing number of publications dealing with dosimetry of [177Lu] have been published in the last years (Fig. 1).

Status quo

In contrast, a recent survey in European centers applying radionuclide therapies has shown, that dosimetry is hardly or never used in more than half of all centers [1]. Moreover, an individualized treatment activity was used...
only in 20% of all centers and in less than 10% activity
was adjusted to organs at risk. These findings are most
probably based on the following factors:

1. Dosimetry is time consuming, labor intensive,
therefore expensive, and costs patient time.
2. In not gamma-emitting radionuclides such as $^{90}$Y
surrogate radionuclides such as $^{111}$Indium are
needed for dosimetry. There is a body of evidence
that the obtained results are not well correlated to
the therapeutic radionuclide, which hampers its
useful clinical application.
3. In order to justify this effort an impact on
treatment is warranted by defining (yet lacking)
thresholds for

- a) Organs-at-risk in order to avoid toxicity
- b) Tumor response in order to improve efficacy

In radiation therapy, for example, thresholds for or-
gans and tumor response are well established and both
heavily influence treatment planning. In contrast, how is
the situation in radionuclide therapy? In general, two or-
gans at risk are considered in PRRT: the kidneys and
bone marrow. Since PRRT using $^{177}$Lu should generally
be preferred over $^{90}$Yttrium due to higher efficacy (no
study has ever reported higher response rates for
$^{90}$YDOTATATE) and less toxicity (especially regarding
nephrotoxicity), this manuscript will solely focus on
$^{177}$LuDOTATATE. Several studies have shown that
higher-grade nephrotoxicity using $^{177}$LuDOTATATE is
almost negligible with an annual loss of kidney function
around 3.4% [2–4]. Nevertheless, a threshold of 23 Gy
derived from radiation therapy is still used particularly
from regulatory bodies. There is no evidence that this
threshold is useful for PRRT. So far, no study has ever
proven a clear correlation of kidney dose and nephrotox-
icty. A recent study has shown that the biological equiva-
 lent dose to the kidneys does not correlate with the
annual loss of glomerular filtration rate [5]. Further on, in
this study some patients received up to 8 treatment cycles
with 7.4 GBq $^{177}$LuDOTATATE without significant
nephrotoxicity. The situation is quite the same with regard
to hematotoxicity. The rate of higher-grade hematotoxic-
ity is considered to be around 10% [2, 3]. In a study with
320 patients grade 3/4, hematotoxicity was correlated with
clinical risk factor such as low leucocytes, impaired kidney
function, age over 70 years, and extensive tumor mass [6].
Bone marrow dose showed a weak, but significant correl-
ation with the change of leucocytes and platelets, but not
with the change of hemoglobin. However, it was not pos-
sible to identify a certain threshold for the risk of develop-
ing hematotoxicity. Especially, the often used threshold of
2 Gy adapted from radioiodine therapy had no proven
use. A reason for this finding might be the high variability
of bone marrow dose depending on the method used.
SPECT-based activity concentration fluctuated 100% (L5
median 24.2 kBq/ml, T11 median 47.8 kBq/ml) depending
on the vertebral body examined [7]. Consequently, bone
marrow doses varied depending on the used method: pla-
nar scintigraphy 0.19 Gy/7.4 GBq, SPECT of L4 0.36 Gy/
7.4 GBq, SPECT of all visible vertebra 0.40 Gy/7.4 GBq,
SPECT of all lumbar vertebra 0.39 Gy/7.4 GBq, and
SPECT of all thoracic vertebra 0.46 Gy/7.4 GBq. In sum-
mary, neither for nephrotoxicity, nor for hematotoxicity
thresholds have been reliably identified.

With regard to tumor response the situation is slightly
better. For pancreatic neuroendocrine tumors a study
showed a significant correlation between tumor dose
and change in size [8]. A comprehensive methodology
was used including repeated SPECT/CT and partial vol-
ume correction in 24 patients. Defining tumor shrinkage
of 30% corresponding to RECIST partial remission as
tumor response a threshold of 170 Gy was identified in tumors larger than 2.2 cm. In contrast, the same group found no correlation between tumor shrinkage and tumor dose (also not for change in tumor volume) in 25 patients with neuroendocrine tumors of the small intestine, despite using the same comprehensive methodology [9]. Notably, only 1/25 patients had partial remission as best response and median tumor shrinkage was 12%. The absorbed tumor dose was 128.6 Gy and comparable to that of pNET in the latter study. A correlation was, however, found between the administered activity and the tumor volume shrinkage ($p = 0.01$) and between the administered activity and RECIST 1.1. response ($p = 0.01$).

**Conclusion**

Radionuclide therapy is currently on a crossroads between fixed treatment schemes and dosimetry-based individualized treatments. For the establishment of individualized PRRT, the currently quite variable dosimetry methods have to be harmonized, that means that the nuclear medicine community has to agree on an accepted and validated dosimetric methodology available for the majority of centers. Same is true for assessment of tumor response and follow-up of patients. In order to pave the road towards individualized treatment large prospective, randomized studies will be necessary identifying reliable and robust thresholds for toxicity and efficacy. These trials will have to prove that an individualized PRRT is superior to standardized PRRT with $4 \times 7.4$ GBq $^{177}$LuDOTATATE, as demonstrated in the NETTER trial [2].

If these developments will not happen, it is most likely development of radionuclide therapies will be done like big pharmaceutical companies do it currently: classical dose escalation studies and agreement on acceptable toxicity probabilities. The development of $^{223}$Radium (Xofigo) by Bayer and $^{177}$LuDOTATATE (Lutathera) by AAA serve as examples of this approach. This approach will naturally neglect individual differences in organ and tumor doses. Therapeutic radiopharmaceuticals will then be handled like other drugs; on the other hand, requirements for users will be low which will increase accessibility of radionuclide therapy. Somewhat provocatively speaking, the implementation of this strategy will not significantly change the situation compared to the current status of radionuclide therapies, but the grade of evidence for it will markedly improve.

**Acknowledgements**

I would like to thank many colleagues with whom I had fruitful discussions about the treatment of NET and dosimetry.

**Authors’ contributions**

AH has written this manuscript. The author(s) read and approved the final manuscript.

**Funding**

None

**Availability of data and materials**

Not applicable

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Not applicable

**Competing interests**

The author(s) declare that they have no competing interests.

**References**

1. Sjogreen Gleisner K, Spezi E, Solny P, Gabina PM, Ciccone F, Stoike C, et al. Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Phys. 2017;4:28. https://doi.org/10.1186/s40658-017-0193-4.
2. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of $^{177}$Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.
3. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog $^{177}$Lu-DOTATATE: toxicity, efficacy, and survival. J Clin Oncol. 2008;26: 2124–30. https://doi.org/10.1200/JCO.2007.15.2553.
4. Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, et al. Nephrotoxicity after PRRT with $^{177}$Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016. https://doi.org/10.1007/s00259-016-3382-9.
5. Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised ($^{177}$Lu)DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–9. https://doi.org/10.1007/s00259-017-3678-4.
6. Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Subacute haematotoxicity after PRRT with ($^{177}$Lu)DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43:453–63. https://doi.org/10.1007/s00259-015-3193-4.
7. Hagmarker L, Svensson J, Ryden T, van Essen M, Sundlov A, Gleisner KS, et al. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ($^{177}$Lu)DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. J Nucl Med. 2019;60:1406–13. https://doi.org/10.2967/jnumed.118.225235.
8. Ilan E, Sandstrom M, Wasberg C, Sundin A, Gunase-Roman U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using $^{177}$Lu-DOTATATE. J Nucl Med. 2015;56:177–82. https://doi.org/10.2967/jnumed.114.148437.
9. Jahn U, Ilan E, Sandstrom M, Gunase-Roman U, Lubberink M, Sundin A, $^{177}$Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors. Neuroendocrinology. 2019. https://doi.org/10.1159/000504001.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.